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A Novel Y-Specific Long Non-
Coding RNA Associated with 
Cellular Lipid Accumulation in 
HepG2 cells and Atherosclerosis-
related Genes
Elsa Molina1, Guat S. Chew1, Stephen A. Myers2, Elyse M. Clarence1, James M. Eales  3, 
Maciej Tomaszewski3 & Fadi J. Charchar1,4,5
There is an increasing appreciation for the role of the human Y chromosome in phenotypic differences 
between the sexes in health and disease. Previous studies have shown that genetic variation within 
the Y chromosome is associated with cholesterol levels, which is an established risk factor for 
atherosclerosis, the underlying cause of coronary artery disease (CAD), a major cause of morbidity 
and mortality worldwide. However, the exact mechanism and potential genes implicated are still 
unidentified. To date, Y chromosome-linked long non-coding RNAs (lncRNAs) are poorly characterized 
and the potential link between these new regulatory RNA molecules and hepatic function in men has 
not been investigated. Advanced technologies of lncRNA subcellular localization and silencing were 
used to identify a novel intergenic Y-linked lncRNA, named lnc-KDM5D-4, and investigate its role in 
fatty liver-associated atherosclerosis. We found that lnc-KDM5D-4 is retained within the nucleus in 
hepatocytes. Its knockdown leads to changes in genes leading to increased lipid droplets formation 
in hepatocytes resulting in a downstream effect contributing to the chronic inflammatory process 
that underpin CAD. Our findings provide the first evidence for the implication of lnc-KDM5D-4 in key 
processes related to fatty liver and cellular inflammation associated with atherosclerosis and CAD in 
men.
The human Y chromosome is best known for its key role in spermatogenesis and testicular development1. It 
is becoming increasingly clear that the biological functions of the Y chromosome transcend the male fertility 
and reproduction2, with associations between genetic variation within the male-specific region of the Y chro-
mosome (MSY) and complex polygenic phenotypes including blood pressure3, circulating cholesterol levels4, 
and coronary artery disease (CAD)2,5 being reported. The mechanisms of these associations are not entirely 
clear although it appears that they are (at least in part) mediated by the expression of MSY genes in the target 
cells and tissues6. To date, over 200 Y-linked genes have been identified and those that encode Y proteins have 
been well-characterised7. However, MSY harbours not only 27 protein-coding genes but also a number of long 
non-coding RNAs (lncRNAs) – important new regulatory molecules implicated in cardiovascular health8 and 
disease9. So far, there is no data on Y chromosome-linked lncRNAs in relation to any human phenotypes. To this 
end, we sought to investigate Y-linked long intergenic non-coding RNAs (lincRNAs) - the largest class within the 
lncRNA group10 - in relation to phenotypes of relevance to CAD such as fatty liver-associated atherosclerosis.
Here, we studied for the first time eleven novel Y-linked lincRNAs by real-time PCR gene expression analysis 
in the human hepatoma HepG2 male cell line, an in vitro model system used in previous studies on liver steatosis 
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and CAD11–14. We also investigated the expression of a novel intergenic Y-linked lincRNA, named lnc-KDM5D-4, 
across 21 normal tissue types. Utilising advanced technologies of lncRNA subcellular localization and silencing, 
we further characterized lnc-KDM5D-4 within HepG2 cells, and investigated the effects of its knockdown on 
atherosclerosis-related genes in these cells. Throughout the text, ‘lnc-KDM5D-4′ refers to the long non-coding 
RNA gene, and ‘lnc-KDM5D-4:1′ refers to the long non-coding RNA transcript.
Materials and Methods
Primer design. The human lincRNA catalogues15,16 were used to select Y-specific lincRNA genes based 
on their expression in tissues relevant to the liver and CAD, such as heart, liver and white blood cells (WBCs) 
(Supplementary Materials and Methods). Primers for SYBR® Green-based real-time polymerase chain reac-
tion (PCR) gene expression analysis were designed using the free online software Primer-BLAST (Basic Local 
Alignment Search Tool) following the recommendations for probe melting temperature (Tm) values, GC content, 
and amplicon length provided by Thornton & Basu17. All the primers for lincRNAs were designed from the DNA 
template sequence annotated on LNCipedia, the database for human lncRNA genes and transcripts18. Primer 
sequences are available in Supplementary Table S1.
HepG2 cell culture and treatments. The human hepatoma cell line, HepG2, obtained by the Charchar 
Laboratory, was grown as a monolayer culture in Dulbecco’s modified Eagle medium (DMEM, 1X) (Gibco®, 
Life Technologies™) supplemented with 10% (v/v) heat inactivated foetal bovine serum (HI-FBS) (Gibco®, 
Life Technologies™), 100 U/mL penicillin, 100 µg/mL streptomycin (Gibco®, Life Technologies™) and were 
incubated at 37 °C in a humidified atmosphere containing 5% (v/v) CO2 in the air. The HepG2 cell model of 
palmitate-induced steatosis and insulin-resistance were developed as previously described19 (Supplementary 
Materials and Methods).
Human tissue RNA panel. The Human Tissue RNA Panel was obtained from Ambion® FirstChoice®Human. 
Total RNA Survey Panel which consists of 10 µg pools of total RNA (stored in 1 mmol/L of sodium citrate) from 
20 different normal, human tissues including adipose, bladder, brain, cervix, colon, esophagus, heart, kidney, liver, 
lung, ovary, placenta, prostate, skeletal muscle, small intestine, spleen, testes, thymus, thyroid, and trachea. Each 
pool is comprised of RNA from 3 tissue donors (with at least 1 male donor per tissue except for the cervix, placenta, 
and ovary RNA sample pools) and underwent a stringent DNase treatment. After storage at −80 °C on arrival, RNA 
samples were thawed at 37 °C then placed on ice prior use as recommended by the manufacturer’s instructions.
Blood collection. To study the expression of lincRNAs expressed in leucocytes in men, five healthy male 
volunteers (positive control group) and two healthy females (negative control group), between 18–50 years old 
were recruited at the Federation University Australia (Mount Helen campus). Participants were required to meet 
the following inclusion criteria: current non-smokers, free of recent surgery, ambulatory aids, and acute joint 
injury, free of underlying medical conditions such as heart disease, un-medicated hypertension and respiratory 
disorders in order to avoid skewing the results. Participants’ blood was withdrawn in Ethylenediaminetetraacetic 
acid (EDTA) blood collection tubes (tubes commonly used in routine haematology and furnished by the phlebot-
omist) by a qualified phlebotomist at Mount Helen campus. Then, blood samples were immediately stored on ice 
and total RNA was purified within an hour of collection to preserve the RNA integrity. This study was approved 
by the Federation University Ethics Committee at Mount Helen campus and carried out in accordance with 
Federation University relevant guideline and regulations. All the subjects gave informed consent [Ethics Project 
Number: B13-020].
Oil Red O cell staining. To confirm steatosis induced by palmitate in HepG2 cells, cellular lipid droplets were 
stained using Oil Red O (ORO) from Hepatic Lipid Accumulation/Steatosis Assay (abcam®) (Supplementary 
Materials and Methods).
Protein extraction and Western Blot analysis. Total cellular protein from HepG2 cells treated with 
insulin over 48 h was isolated by scraping the cells with Pierce® RIPA buffer. A total soluble protein (50 μg) 
was resolved on a 4–15% SDS-PAGE gradient gel (BIORAD®) and transferred to a nitrocellulose membrane 
(Supplementary Materials and Methods).
Total RNA isolation. Total RNA was extracted from cells using TRIzol reagent (Ambion®). Total RNA was 
resuspended in 50 µL RNase-free water followed by a column DNase treatment (1 µL per RNA sample) using 
Recombinant DNase I (Ambion®, Applied Biosystem®) according to the manufacturer’s instructions. RNA 
yield and purity were measured by absorbance using a NanoDrop™ 2000 Spectrophotometer (Thermo Fisher 
Scientific®, Australia). The ratio (A260 nm/A280 nm) of ~2.0 was accepted as “pure” for RNA. Finally, RNA samples 
were stored at −80 °C until use.
Synthesis of cDNA and real-time PCR. RNA (2 µg) was reverse transcribed into cDNA with the High 
Capacity Reverse Transcription Kit (Life Technologies®). Real-time PCR was assessed in triplicate and carried 
out using SYBR® Green (Bioline®) according to the manufacturer’s instructions. Data were analysed using the 
2-delta delta CT method20. CT results were normalised with two housekeeping genes, ACTB (or GAPDH) and UBC 
(Supplementary Materials and Methods).
RNA fluorescence in situ hybridization (RNA FISH). RNA FISH was performed using the advanced 
QuantiGene® ViewRNA ISH Cell Assay (Affymetrix®). The permeabilisation procedure was amended and 
1% glacial acetic acid was added to the fixation solution to detect nuclear RNAs21, then the RNA FISH assay 
www.nature.com/scientificreports/
3SCIeNTIFIC RepoRts | 7: 16710  | DOI:10.1038/s41598-017-17165-9
from Four-Chambered Dish Format protocol was performed according to the manufacturer’s instructions 
(Supplementary Materials and Methods).
Nuclear and Cytoplasmic RNA fraction isolations. Nuclear and cytoplasmic RNA fractions were iso-
lated separately from confluent cells using the Cytoplasmic & Nuclear RNA Purification Assay (Norgen Biotek 
Corp.®, Canada) according to the manufacturer’s instructions. Both RNA fractions, nuclear and cytoplasmic, 
were resuspended in 50 µL RNase-free water followed by a column DNase treatment (1 µL per 1000 ng of RNA) 
using the Recombinant DNase I (Ambion®, Applied Biosystem®) according to manufacturer’s instructions. RNA 
yield and purity were measured by absorbance using a NanoDrop™ 2000 Spectrophotometer (Thermo Fisher 
Scientific®, Australia). The ratio (A260 nm/A280 nm) of ~2.0 was accepted as “pure” for RNA. Finally, the RNA sam-
ples were stored at −80 °C until use.
Cell transfection and lncRNA knockdown. Advanced antisense oligonucleotides (AOs) Locked Nucleic 
Acid (LNA™) longRNA GapmeRs - a class of high-affinity RNA analogues that exhibit high thermal stability 
when hybridized to a complementary DNA or RNA strand - were used to silence lnc-KDM5D-4. Antisense 
LNA™ longRNA GapmeRs were custom designed (except for the control GapmeR ‘Negative control A’) and 
Figure 1. Identification of Y chromosome lincRNAs in HepG2 cells. (A) Steps followed in the identification 
process of Y-specific lincRNAs. (B) Y-specific lincRNA real-time PCR analysis. Lnc-KDM5D-4:1, lnc-ZFY-1:1, 
lnc-ZFY-1:3, lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4, lnc-PRY-1:1, lnc-PRY-1:2, lnc-PRY-1:3, lnc-
USP9Y-1:4, and lnc-HSFY2-3:6 normalised expression values with respective S.E.M. relative to actin beta 
(ACTB) housekeeping gene. HULC – a lincRNA with confirmed up-regulation in HepG2 cells - used as a 
positive control (n = 3).
www.nature.com/scientificreports/
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Figure 2. Expression of MSY lincRNAs in palmitate-induced steatosis and in insulin-resistant HepG2 cells. 
(A,B) Quantification of the lipid accumulation by absorbance measurement after treatment with palmitate at 
0.3 mmol/L (0.3 mM) (A), and chloroquine (as positive control) at 25 µmol/L (25 µM) (B). Microscopy results 
of the intracellular distribution of lipid droplets stained in red by the Oil Red O solution after 24 h of treatment 
with either the vehicle or with the palmitate (C). The addition of palmitate after 24 h triggers a significant 
increase (Fold Change = 2.16; p-value = 0.00216) in the expression of lnc-KDM5D-4:1 in HepG2 cells in 
comparison to cells not treated with palmitate (control cells) (D). No significant increase in the expression of 
lnc-ZFY-1:1, lnc-ZFY-2.1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4, lnc-USP9Y-1:4, lnc-HSFY2-3:6, and HULC 
is observed. (E) Western blot analysis of phosphorylated protein kinase B (pAkt), Total Akt, phosphorylated 
insulin-receptor (pIR), and Total IR (gel cropped). Antibodies were used to immunodetect the levels of pAkt, 
Total Akt, pIR and Total IR in an increasingly insulin-resistance HepG2 cell line. For protein phosphorylation 
detection, 10 nM insulin was added for 30 min before cell lysates harvest at the indicated time. Western blot 
analysis was performed on two independent experiments (Uncropped gel images Supplementary Figure S1).  
www.nature.com/scientificreports/
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synthesized by Exiqon®. Three different GapmeRs targeting three different sites of lnc-KDM5D-4:1 RNA were 
used following the Exiqon’s recommendations. The transfection of the following GapmeRs, lnc-KDM5D-4_
GapmeR_1 (Product sequence 5′-3′: GAGATGAAGCGGAATT), lnc-KDM5D-4_GapmeR_2 (Product sequence 
5′-3′: CTTACTTTAGACTTC), lnc-KDM5D-4_GapmeR_3 (Product sequence 5′-3′: ACGTAAAATAGGATTA), 
and Negative control A (Product sequence 5′-3′: AACACGTCTATACGC) were performed using Lipofectamine® 
2000 (Thermo Fisher Scientific®) following Exiqon manufacturer’s recommendations as well as those for knock-
down of lncRNA and AOs provided by Integrated DNA Technologies®’s webinars on www.youtube.com/user/
idtdnabio. HepG2 cells were seeded into 6-well plates at a density of ~2 × 105/mL and cultured in DMEM sup-
plemented with 10% HI-FBS, penicillin (100 U/mL), and streptomycin (100 µg/mL) until the cells reached ~70% 
confluence. Then, the cells were transfected with 10 nmol/L of AO in Lipofectamine® 2000 reagent. After 48 h, 
total RNA was extracted using TRIzol reagent followed by a RNA clean-up step using miRNeasy kit (Qiagen®). 
Then, the knockdown was confirmed by real-time PCR.
Reverse transcription and Atherosclerosis RT2 Profiler™ PCR Array. The Human Atherosclerosis 
RT2 Profiler PCR Array (PAHS-038ZE) from SA Biosciences (Qiagen®; Catalogue No. 330231) was performed 
following the manufacturer’s recommendations (Supplementary Materials and Methods). Then, the human 
tissue-specific network webserver GIANT22 was used to generate the potential tissue-specific functional interac-
tions between the atherosclerosis-relevant genes.
Statistical analysis. Statistical analysis of data was performed using Prism (GraphPad Software). Data were 
analysed using a Student’s unpaired t-test to test significance of data comparisons between cell treatments, with 
p-values < 0.05 considered as statistically significant.
Results
A survey of the expression of novel Y chromosome-linked lincRNAs in HepG2 cells. Using 
human lncRNA reference catalogues15,16 which include the Y chromosome, we identified 11 candidate MSY 
lincRNA transcripts and measured their expression in the human hepatoma HepG2 cell line. Seven MSY lin-
cRNA transcripts such as lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4, 
lnc-USP9Y-1:4, and lnc-HSFY2-3:6 were found to be expressed in the HepG2 cells (Fig. 1A,B). Their average 
abundance was significantly lower than that of lncRNA HULC (Hepatocellular carcinoma up-regulated long 
non-coding RNA) which was used as a positive control23.
The effects of fatty acid palmitate on the transcript expression of Y chromosome-linked lincR-
NAs in a steatosis HepG2 cell line. Positive correlations between CAD and high levels of free fatty acids 
(FFAs) in steatosis hepatocytes have been previously demonstrated in vitro using HepG2 cells11–14. To create a 
FFA-induced steatosis liver cell line, HepG2 cells were stimulated with 0.3 mmol/L of palmitate for 24 hours to 
induce lipid accumulation within the cells14. Two methods were used to assess the results: quantification of the 
lipid accumulation by absorbance measurement (Fig. 2A,B) and examination of the intracellular distribution 
of lipid droplets by Oil Red O (ORO) staining using microscopy (Fig. 2C). To confirm the ability of our assay 
to generate the required cell phenotypes, we compared the magnitude of lipid accumulation within the target 
cells with that generated by the positive control for inducing steatosis, the chloroquine (based on manufacturer’s 
recommendations). Results with chloroquine showed a similar significant increase in lipid accumulation within 
the treated cells when compared to the control cells (Fig. 2A). The absorbance measurement of the lipid quan-
tification (Fig. 2B) suggested that HepG2 cells had acquired the palmitate-induced steatosis phenotype. These 
results were further validated by microscopy demonstrating a clear increase of ORO-stained lipid droplets (red) 
in the peri-nuclear region of the cells in comparison to the control cells (Fig. 2C). Real-time PCR results showed 
that 24 h-treatment with palmitate triggered a significant 2.16-fold increase in the expression of lnc-KDM5D-4:1 
(p-value = 0.00216) in HepG2 cells. No significant increase in the expression of the transcripts lnc-ZFY-1:1, 
lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4, lnc-USP9Y-1:4, lnc-HSFY2-3:6, and HULC was observed 
(p-value > 0.05) (Fig. 2D).
The effects of insulin on the lncRNA transcript lnc-KDM5D-4:1 expression in an insulin-resistant 
HepG2 cell line. To investigate the possible correlation between steatosis and insulin-resistance, the potential 
effect of insulin resistance on the expression of lnc-KDM5D-4 was studied. To create an insulin-resistant cell 
line, HepG2 cells were stimulated with 10 nM of insulin solution over 0, 0.25, 0.5, 2, 4, 8, 24, and 48 h replacing 
the media and insulin every 8 h. Total cellular protein was extracted using RIPA buffer and 20 μg of total cellular 
protein was subjected to SDS-PAGE, and subsequently blotted onto Immobilon-PVDF membrane. The relative 
levels of phosphorylated protein kinase B (pAkt) or phosphorylated insulin-receptor (pIR) were detected relative 
to Total Akt and Total IR respectively (Fig. 2E). Western blot analysis showed that following 30 min of insulin 
treatment, there was an increase in the levels of pAkt that were further increased at 2 and 4 h of insulin treatment, 
as similarly for pIR. The level of phosphorylation then rapidly decreased at 8 h and became almost undetectable 
at 24 and 48 h. The level of phosphorylation of the IR decreased from 24 h. Overall, there was no change in Total 
(F) Real-time PCR results of the 24 h insulin-stimulated HepG2 cells with no significant changes in the 
expression of lnc-KDM5D-4:1 in comparison to the cells not treated (control cells) (Fold Change = 1.39; 
p-value > 0.05). Data are relative to the housekeeping gene actin beta (ACTB). Error bars indicate ± SD 
calculated from sextuplicate wells (A,B). NT, no treatment; (n = 4). Statistical significance: *p-value < 0.05; **p-
value < 0.01.
www.nature.com/scientificreports/
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Akt and IR proteins observed, suggesting that the cells had obtained the insulin-resultant phenotype (Fig. 2E). 
To determine if lnc-KDM5D-4 responded to insulin-resistance, its expression was analysed by real-time PCR. 
Results showed no significant change in the expression of lnc-KDM5D-4 in cells stimulated with insulin for 24 h 
compared to the control cells (Fig. 2F).
A survey of the expression of the lncRNA transcript lnc-KDM5D-4:1 in 21 different normal 
human tissues. To gain a better understanding about the biological role of lnc-KDM5D-4, we examined 
its expression across 21 normal human tissue types including adipose, bladder, brain, cervix, colon, esophagus, 
heart, kidney, liver, lung, ovary, placenta, prostate, skeletal muscle, small intestine, spleen, testes, thymus, thyroid, 
trachea, male and female leucocytes from WBCs. The real-time PCR analysis revealed that lnc-KDM5D-4 shows 
ubiquitous expression with the highest level of expression in the spleen and the heart. As expected, no expression 
was found in female tissues such as cervix, ovary, and placenta as well as in female leucocytes (Fig. 3).
Subcellular localization of lnc-KDM5D-4:1 transcripts in HepG2 cells. To gain fundamental insights 
into the biology and potential cellular role of lnc-KDM5D-4 in the regulation of cellular functions24, we exam-
ined its subcellular localization using RNA fluorescence in situ hybridization (RNA FISH) with single-molecule 
sensitivity. To achieve a controlled system as background image, the assay was performed without addition of 
glacial acetic acid (AA) to the fixation solution (Fig. 4A,C,E). This way, although significant cytoplasmic signals 
were observed for the actin beta (ACTB) housekeeping gene probe (green) (Fig. 4C), any signal obtained was the 
result of the lnc-KDM5D-4:1 probe (red) (Fig. 4E). These results suggested that lnc-KDM5D-4:1 transcripts were 
localised only in the nucleus. By adding 1% of AA into the fixation solution, the fluorescence of single-RNA mol-
ecule of lnc-KDM5D-4:1 (red) displays a strictly nuclear distribution (Fig. 4F,G and Supplementary Video S1). 
The ACTB RNA FISH results (Fig. 4C,D) confirmed the efficiency of reagents and methods used for this assay. 
As negative controls, wells with only secondary probes were tested and no signal displays were seen, as expected, 
(Fig. 4A,B) confirming that signals obtained for ACTB and lnc-KDM5D-4:1 are not due to the mere expression 
of the secondary probes. RNA FISH results were then confirmed by real-time PCR using nuclear and cytoplasmic 
RNAs, separately isolated from HepG2 cells, as shown in Fig. 4H.
The effects of lnc-KDM5D-4 knockdown on genes in HepG2 cells. To elucidate the potential biolog-
ical role of Y-linked lnc-KDM5D-4 in the liver, a knockdown using the advanced Locked Nucleic Acid GapmeRs 
(antisense oligonucleotides (AOs)) that blocked lnc-KDM5D-4:1 activity was performed. This was followed by a 
gene expression analysis using the RT2 Profiler PCR Array. Specifically, we transfected HepG2 cells with GapmeRs 
targeting lnc-KDM5D-4:1 using three different probes separately (lnc-KDM5D-4_GapmeR_1, lnc-KDM5D-4_
GapmeR_2 and lnc-KDM5D-4_GapmeR_3) to target three different sites of lnc-KDM5D-4:1. A random scram-
bled sequence that contains no known homology to the human, mouse, or rat genome was used as a negative 
control. Cells without transfection (Untreated) were also used to verify the Scramble (negative control probe) for 
non-specificity. Cells were harvested 48 h after transfection. AO-mediated silencing of lnc-KDM5D-4 was assessed 
in real-time PCR. The highest knockdown efficiency was obtained when the cells are treated with 10 nmol/L of the 
lnc-KDM5D-4_GapmeR_1 with a transcript reduction of 88% (Fold change = 0.12; p-value = 0.0008). The compar-
ison of transfected cells with GapmeRs and Scramble (control GapmeR) to Untreated samples showed that there was 
no significant effect of transfection reagent or transfection reagent plus GapmeR respectively, on the cell (Fig. 5A).
Figure 3. Lnc-KDM5D-4 gene expression analysis in healthy human tissues. The expression of lnc-
KDM5D-4:1 in 21 different normal, human tissues – real-time PCR (no expression observed in female tissues 
such as cervix, ovary, placenta, and female leucocytes), the expression estimates are relative to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), and error bars indicate ± S.E.M. (n = 3).
www.nature.com/scientificreports/
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Following that, the Human Atherosclerosis RT2 Profiler PCR Array was used to compare cells transfected with 
the lnc-KDM5D-4_GapmeR_1 and cells transfected with the control GapmeR (Scramble) (Fig. 5B,C). This array 
profiled the expression of 84 genes related to atherosclerosis. Our results showed that reduced lnc-KDM5D4:1 
transcript level in HepG2 cells was associated with changes in expression of 11 genes: BIRC3 (baculoviral IAP 
repeat containing 3), EGR1 (early growth response 1), MMP3 (matrix metallopeptidase 3), IL1A (interleukin 1 
Figure 4. Subcellular localization of lnc-KDM5D-4:1 in HepG2 cells. (A,B) Cells without probes (negative 
control). (C,D) actin beta (ACTB fluorescence in situ hybridization (ACTB-FISH) (green) used as housekeeping 
gene and positive control for the RNA FISH assay. (F,G, and Supplementary Video S1) RNA FISH shows 
the nuclear localization of lnc-KDM5D-4:1 (red). Each probe was tested with (B,D,F,G, and Supplementary 
Video S1) or without (A,C,E) addition of 1% of acetic acid (AA) at the cell fixation step. This resulted in no 
observable nuclear signal for lnc-KDM5D-4:1 when AA is not added to the fixation solution (E). (H) Real-time 
PCR lnc-KDM5D-4:1 transcript expression results from nuclear and cytoplasmic RNAs isolated separately from 
HepG2 cells before reverse transcription, then real-time PCR. Results show a nuclear expression, exclusively, of 
lnc-KDM5D-4:1 in comparison to ACTB which is approximately half nuclear and half cytoplasmic. Microscopy 
confocal images represent three independent experiments (n = 3). Confocal microscope magnification: 60x.
www.nature.com/scientificreports/
8SCIeNTIFIC RepoRts | 7: 16710  | DOI:10.1038/s41598-017-17165-9
Figure 5. Lnc-KDM5D-4 knockdown and associated atherosclerosis-relevant genes. Cells were transfected 
with Locked Nucleic Acid (LNA) GapmeRs targeting lnc-KDM5D-4:1 RNA or random scrambled sequence. 
(A) Cells were harvested 48 h after transfection. AO-mediated silencing of lnc-KDM5D-4 was assessed 
in real-time PCR (normalised to ACTB as housekeeping control gene). The cells demonstrate antisense 
oligonucleotide knockdown of nuclear-located lnc-KDM5D-4 with the 3-different tested GapmeRs; a highest 
knockdown efficiency was achieved with the lnc-KDM5D-4_GapmeR_1 [transcript reduction by 88% (Fold 
change = 0.12; p-value = 0.0008)]. Comparison of transfected cells with GapmeRs, and Scramble to Untreated 
samples (negative control) showed that there was no significant effect of transfection reagent or transfection 
reagent plus GapmeR respectively on the cell. (B,C) A Human Atherosclerosis RT2 Profiler™ PCR Array was 
utilized to profile the expression of 84 genes involved in atherosclerosis between HepG2 cells transfected with 
GapmeR targeting lnc-KDM5D-4 (lnc-KDM5D-4_GapmeR_1) and scrambled cells. Relative expression levels 
of these genes were normalised to a set of housekeeping genes (Supplementary Table S6). Three independent 
biological samples were used (n = 3). The volcano plot combines a p-value statistical test with the fold change 
enabling identification of genes with both large and small expression changes that are statistically significant 
are represented; upregulated genes (red), downregulated genes (green), and unchanged genes (black) (B). 
In transfected cells compared to untransfected cells, results determine that 9 genes were significantly over-
expressed ((p-value < 0.05; Fold Change >2): BIRC3 (baculoviral IAP repeat containing 3), EGR1 (early growth 
response 1), MMP3 (matrix metallopeptidase 3), IL1A (interleukin 1 alpha), BCL2 (BCL2, apoptosis regulator), 
SERPINE1 (serpin family E member 1), VEGFA (vascular endothelial growth factor A), PLIN2 (perilipin 2), and 
ITGA2 (integrin subunit alpha 2); and 2 genes were significantly under-expressed ((p-value < 0.05; Fold Change 
<−2.00): ITGA5 (integrin subunit alpha 5), and TNF (tumor necrosis factor) (C). The significant dysregulated 
genes are summarized in Supplementary Figure S2 with their pathways associated with the most represented 
‘anti-apoptosis pathway’. Statistical significance: *p-value < 0.05; **p-value < 0.01; ***p-value < 0.001.
www.nature.com/scientificreports/
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alpha), BCL2 (BCL2, apoptosis regulator), SERPINE1 (serpin family E member 1), VEGFA (vascular endothelial 
growth factor A), PLIN2 (perilipin 2), ITGA2 (integrin subunit alpha 2), ITGA5 (integrin subunit alpha 5), and 
TNF (tumor necrosis factor) (Fig. 5C). Most of these genes mapped to anti-apoptosis pathway (Supplementary 
Fig. S2). Finally, the new human tissue-specific network webserver GIANT22 was used to highlight the potential 
functional interactions of these genes with other protein-coding genes in hepatocytes (Supplementary Fig. S3).
Previous studies on transcriptional regulation models showed that lncRNAs, notably lincRNAs, may operate 
in cis by regulating their immediate neighbouring protein-coding genes leading to either an increase or reduction 
of their expression16,25,26. After confirmation of the lnc-KDM5D-4 knockdown in HepG2 cells, we examined the 
potential transcriptional activity of the nearest neighbouring protein-coding genes by lnc-KDM5D-4 such as 
KDM5D (lysine demethylase 5D), EIF1AY (eukaryotic translation initiation factor 1A, Y-linked), and RPS4Y2 
(ribosomal protein S4, Y-linked 2) located within 1.1 MB window centred on lnc-KDMM5D-4. Real-time PCR 
analysis showed that there were no significant changes (p-value > 0.05) in the expression of these neighbouring 
Y chromosome protein-coding genes in cells transfected with the lnc-KDM5D-4_GapmeR_1 compared to the 
control cells (Scramble) (Fig. 6).
Discussion
Genetic variation within the Y chromosome has been linked to human lipid levels and cardiovascular dis-
ease2–4,6,27,28. Here we provide novel data suggestive of a potential role for one of the Y chromosome lin-
cRNA, lnc-KDM5D-4, in the hepatic metabolism of lipids and atherosclerosis. Our findings demonstrate that 
lnc-KDM5D-4 is a nuclear-retained lincRNA that has a regulatory effect on the mRNA expression of genes such 
as Perilipin 2 (PLIN2), that in turn, lead to increased lipid droplets formation in hepatocytes. We propose that this 
link may, in part, contribute to the association between certain Y chromosome haplogroups and atherosclerosis.
There is currently no information regarding Y chromosome-linked lncRNAs in human traits and disease. 
This is due to the fact that the Y chromosome is routinely excluded from genome analysis studies into the identi-
fication and the functions of lncRNAs in mammals29,30. Indeed, due to the haploid nature of the Y chromosome, 
Figure 6. Schematic representation of protein-coding genes surrounding the lncRNA gene lnc-KDM5D-4 on 
the human Y chromosome. Protein-coding genes within 1.1 MB window centred on lnc-KDM5D-4. Upstream 
genes: EIF1AY (eukaryotic translation initiation factor 1A, Y-linked), which encodes for two transcripts, 
and RPS4Y2 (ribosomal protein S4, Y-linked 2). Downstream genes: KDM5D (lysine demethylase 5D). The 
knockdown of lnc-KDM5D-4 in HepG2 cells does not influence the expression of its nearest neighbouring 
protein-coding genes. MSY: male-specific region of the Y chromosome. PAR1: pseudo-autosomal region 1. 
PAR2: pseudo-autosomal region 2. Position on the Y chromosome in base pair (bp); Human GRCh38/hg38.
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the usual methods of analysis (such as genome-wide association studies (GWAS)) cannot be employed to 
investigate variations. This study provides the first evidence of the expression of Y-linked lincRNA transcripts 
such as lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4, lnc-USP9Y-1:4, and 
lnc-HSFY2-3:6 in human hepatocellular carcinoma (HCC). Further research focusing on these lincRNAs between 
primary human hepatocytes and HepG2 cells should be done as these lincRNAs may also play a role in HCC, and 
could be potential biomarkers for the diagnosis of this cancer in men. Our data also provides the first evidence 
for the up-regulation of the Y-linked lincRNA, known as lnc-KDM5D-4, in response to palmitate treatment in 
HepG2 cells. However, lnc-KDM5D-4 was not differentially expressed or affected in insulin-resistance HepG2 
cells, demonstrating that the results found with the steatosis cell model were independent of those found in the 
insulin-resistance cells. These results confirmed that the significant changes in expression of lnc-KDM5D-4 after 
the FFA-palmitate treatment was triggered by the steatosis phenotype, and not by the insulin-resistance pheno-
type. It was suggested that lnc-KDM5D-4 was then implicated in hepatic steatosis which can occur independently 
of insulin resistance in the liver. Given the role of FFAs in the pathogenesis of CAD31–33, these results suggest that 
lnc-KDM5D-4 may play a role in the hepatic metabolism of lipids – a process of well-known relevance to athero-
sclerosis. Whether aberrant expression of this lincRNA plays an insignificant role in this context, or if it is a mere 
consequence of disease pathology remains an open question. Further research on lnc-KDM5D-4 should be done 
to study the role of this Y-linked lincRNA in steatosis-associated atherosclerosis.
Lnc-KDM5D-4:1 transcripts were found to be expressed in adipose, bladder, brain, colon, esophagus, heart, 
kidney, liver, lung, prostate, skeletal muscle, small intestine, spleen, testes, thymus, thyroid, trachea, and leuco-
cytes suggesting that this lincRNA is widely expressed in male tissues. These findings provide a novel expression 
profile for lnc-KDM5D-4 across human healthy tissues. Based on these data, we believe that this lincRNA may 
have other molecular and physiological roles in men.
Figure 7. Schematic diagram illustrating the potential role of lnc-KDM5D-4 in atherosclerosis. Atherosclerosis 
is driven by a chronic inflammatory process. Lipid disturbances and other risk factors are thought to cause 
endothelial injury resulting in monocyte adhesion and migration to the intima, as well as the release of 
cytokines and growth factors. Low-density lipoprotein (LDL) particles travelling in the blood and carrying 
cholesterol and triglycerides from the liver to other body tissues get through the endothelium layer due to their 
size and density, and become oxidized. After migration to the sub-endothelial space, monocytes differentiate 
into macrophages, which are then able to ingest oxidized-LDL, forming specialized foam cells. Macrophages 
are not able to process the oxidized-LDL and ultimately grow and rupture depositing a greater amount of 
oxidized cholesterol into the artery wall. This triggers the recruitment of more monocytes, thus increasing 
the inflammation and continuing the cycle. This inflammation leads to subendothelial accumulation of fatty 
substances called atheromatous plaques. In the hepatocytes, the underexpression of the Y chromosome-linked 
lincRNA lnc-KDM5D-4 results in an overexpression of the gene perilipin 2 (PLIN2) involved in lipid droplet 
formation within the cells. This increase of expression of PLIN2 may consequently initiates the ‘fatty liver’ or 
hepatic steatosis promoting atherosclerosis in the coronary arteries of men.
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The main known function of lncRNAs to date is regulation of gene expression34. Lnc-KDM5D-4:1 RNA FISH 
results suggested that lnc-KDM5D-4:1 is a lincRNA retained within the nucleus of hepatocytes. Concomitantly, 
these findings were in agreement with the previous observations showing that lncRNA transcripts were enriched 
in the cell nucleus in HepG2 cells16. This clearly showed that lnc-KDM5D-4 plays a potential role in biological 
functions taking place within the nucleus24,35 such as the establishment and maintenance of nuclear domains36, 
shaping of the 3D organization35,37, or acting as enhancer-like RNA by activating its neighbouring genes using a 
cis-mediated mechanism38,39. Indeed, an exclusively nuclear localization would argue against putative lncRNAs 
encoding short peptide sequences as translation occurs in the cytoplasm. However, given that its silencing does not 
affect the expression of its surrounding protein-coding genes, this may argue that it acts in trans rather than in cis.
Among the genes that were affected by lnc-KDM5D-4 knockdown in HepG2 cells, PLIN2 is known to be 
implicated in lipid metabolism. This protein-coding gene is located on chromosome 9 and belongs to the perilipin 
gene family that regulate intracellular lipid storage droplets and very low-density lipoprotein (VLDL) secretion40. 
Overexpression of PLIN2 has been shown to trigger an increase in lipid droplets formation within hepatocytes 
via the up-regulation of the peroxisome proliferator-activated receptor gamma isoform (PPAR gamma)41. 
Furthermore, the up-regulation of PLIN2 was previously associated with liver steatosis42 and atherogenesis43. 
More recently, PLIN2 expression was also associated with atherosclerosis in patients with carotid stenosis44. On 
the other hand, the loss of PLIN2 has resulted in reduction of liver steatosis and inflammation45. An overview of 
the involvement of lnc-KDM5D-4 and its potential interaction with PLIN2 in the context of atherosclerosis and 
CAD is proposed in Fig. 7.
Lnc-KDM5D-4 seems to be not conserved between human and rodents18 which could be due to the unique forces 
that drive the evolution of the Y chromosome. It is therefore not possible to study further this lncRNA in rodents.
In conclusion, this is the first study on lincRNAs on the human Y chromosome and gene expression analysis. 
We provide evidence for the potential involvement of one of these lncRNAs, lnc-KDM5D-4, in atherosclerosis 
and CAD, possibly through the lipid metabolism-associated gene PLIN2 in hepatocytes. Overall, our data adds to 
the evidence that the human Y chromosome plays an important role in cardiovascular disease in a male specific 
manner and provides novel insight into potential new therapeutic targets for CAD.
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